Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia

Abstract

The paper considers whether a current treatment option for rheumatoid arthritis with genetically engineered biological agents that selectively block the activity of individual proinflammatory mediators and cell surface antigens involved in autoimmune inflammation may be performed in Karelia, which can achieve control of the disease, retard its progression, and improve prognosis.

Keywords

• генно-инженерные биологические препараты
• инфликсимаб
• моноклональные антитела
• ревматоидный артрит
• ритуксимаб
• фактор некроза опухоли α